NetworkNewsBreaks – Cellectar Biosciences, Inc. (NASDAQ: CLRB) Reports Positive Data from Phase I Trial of CLR 131 in Multiple Myeloma; Shares Higher

Cellectar Biosciences (NASDAQ: CLRB) this morning issued a positive update of its phase I clinical study of CLR 131 in patients with relapsed or refractory multiple myeloma. The data show that the 25 mCi/m2 dose was safe and well tolerated, and that adverse events were similar to those in the previous two cohorts. All four cohort 3 patients achieved stable disease and continue to be followed for progression-free survival (PFS) and median overall survival (mOS). While it is premature to report survival-related efficacy data from cohort 3, all patients in cohorts 1 and 2 continue to experience overall survival benefit.  Additionally, all evaluable patients in the first two cohorts experienced PFS. The median PFS is 92 days for cohort 1 and 133 days for cohort 2, with one cohort 2 patient continuing to experience PFS. “Based on these results, we look forward to providing a full Cohort 3 data update and the imminent initiation of our Phase II clinical trial of CLR 131 in multiple myeloma and other blood cancers, as well as the exploration of additional clinical benefits provided by a second dose midway through the Phase II trial,” president and CEO Jim Caruso stated in the news release.

To view the full press release, visit:

About Cellectar Biosciences, Inc.

Cellectar Biosciences is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar’s PDC platform is based on the company’s proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. Cellectar’s PDC pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. The company’s lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. CLR 131 is currently being evaluated under an orphan drug designated phase I clinical study in patients with relapsed or refractory multiple myeloma. In addition, the company plans to initiate a phase II clinical study to assess efficacy in a range of B-cell malignancies in the first quarter of 2017. The company is also developing PDCs for targeted delivery of chemotherapeutics such as paclitaxel (CLR 1603-PTX), a preclinical-stage product candidate, and plans to expand its PDC chemotherapeutic pipeline through both in-house and collaborative R&D efforts. For more information please visit

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, visit

Please see full disclaimers on the NetworkNewsWire website:

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s